ABSTRACT
The ideal radiopharmaceutical for thorn thombophleboscintigraphy should permit to answer rapidly and accurately the questions whether a patient has, or does have, thrombosis or presents a condition likely to lead to it. The investigations conducted with this ideal radiopharmaceutical should also have prognostic value, permit the selection of therapy and allow the investigator to monitor clot lysis, be the latter spontaneous or therapeutic. The ideal radiopharmaceutical should do all of this, irrespective of the evolutionary stage of the thombosis as well as of the therapeutic or physiological attempts to obtain clot lysis. The biological behaviour of the product should yield evidence of those differences, rather than being neutralized by them. Consequently, this radiopharmaceutical should be rapidly extracted from the blood while accumulating in the thrombus and/or on to damaged vascular endothelium. The elution volume is limited to prevent elution of radioactive components from the column, but adjusted to have the radioactivity distribution span the entire column length.
